# US 10,765,716 B2 · Obesity treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,716 B2
- Document ID: US10765716B2
- Status: Granted
- Kind: B2
- Application number: 15/671,191
- Filed: 2017-08-08
- Published: 2019-02-14
- Granted: 2020-09-08
- Earliest claimed: 2017-08-08
- Applicants: Muhammad Iqbal Choudhary; Sammer Yousuf; Misha Siddiqui; Madiha Mukhtar
- Inventors: Muhammad Iqbal Choudhary; Sammer Yousuf; Misha Siddiqui; Madiha Mukhtar
- Web page: https://patentgrep.com/patent/US10765716B2

## CPC

- A61K 36/30: Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 2236/33: involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for treating the onset of obesity, reducing dyslipidemia and improving insulin sensitivity in mammals comprising administering a therapeutically effective amount of dried alcoholic extract of Cordia latifolia orally at a dose of 300 mg/kg of body weight to mammals in need for the reducing body weight and managing diabetic conditions.

## Claims

### Claim 1

A method for treating onset of obesity in mammals comprising administering a therapeutically effective amount of dried alcoholic extract of Cordia latifolia orally at a dose of 300 mg/kg of body weight to mammals in need for the treatment.

### Claim 2 (depends on 1)

The method of claim 1, wherein the treatment further results in increased insulin sensitivity, lower fasting blood glucose levels, reduced dyslipidemia, serum triglyceride, and very low density lipoprotein (VLDL).